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ABSTRACT  
Background:  
Childhood risk factors are associated with elevated inflammatory biomarkers in adulthood, but it is unknown 
whether these risk factors are associated with increased adult levels of the chronic inflammation marker 
soluble urokinase plasminogen activator receptor (suPAR).  
We aimed to test the hypothesis that childhood exposure to risk factors for adult disease is associated with 
elevated suPAR in adulthood and to compare suPAR with the oft-reported inflammatory biomarker C-
reactive protein (CRP).  
Methods:  
Prospective study of a population-representative 1972-73 birth cohort; the Dunedin Multidisciplinary Health 
and Development Study observed participants to age 38 years. 
Main childhood predictors were poor health, socioeconomic disadvantage, Adverse Childhood Experiences 
(ACEs), low IQ, and poor self-control. Main adult outcomes were adulthood inflammation measured as 
suPAR and high-sensitivity CRP (hsCRP).  
Results:  
Participants with available plasma samples at age-38 were included (N=837, 50.5% male). suPAR (mean 
2.40 ng/mL; SD 0.91) was positively correlated with hsCRP (r 0.15, p<.001).  
After controlling for sex, BMI, and smoking, children who experienced more ACEs, lower IQ, or had poorer 
self-control showed elevated adult suPAR.  
When the five childhood risks were aggregated into a Cumulative Childhood Risk index, and controlling for 
sex, BMI, and smoking, Cumulative Childhood Risk was associated with higher suPAR (b 0.10; SE 0.03; 
p=.002). Cumulative Childhood Risk predicted elevated suPAR, after controlling for hsCRP (b 0.18; SE 
0.03; p<.001).  
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Conclusions:  
Exposure to more childhood risk factors was associated with higher suPAR levels, independent of CRP. 
suPAR is a useful addition to studies connecting childhood risk to adult inflammatory burden.  
Keywords:  
Adverse childhood experiences; self-control; inflammation; physical health; risk factors.  
Abbreviations:  
ACE, adverse childhood experience; BMI, body mass index; CI, confidence interval; CRP, C-reactive 
protein; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; IQ, intelligence quotient; NZ, New 
Zealand; OR, odds ratio; SD, standard deviation; SE, standard error; SES, socioeconomic status; suPAR, 
soluble urokinase plasminogen activator receptor; WBC, white blood cell.  
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INTRODUCTION 
A major public-health challenge is to extend healthspan (i.e., the years lived free of disease and disability) in 
the context of an expanding aging population (Burch et al., 2014; Harper, 2014). Because of evidence that 
the basic foundations for lifelong health are constructed in the early years of life (Power, Kuh, & Morton, 
2013), efforts to extend healthspan are no longer confined to gerontology but also need to involve expertise 
from health professionals specializing in childhood and adolescence (Moffitt, Belsky, Danese, Poulton, & 
Caspi, 2017). Life-course research has drawn attention to several childhood risk factors that may 
compromise lifelong health (Miller, Chen, & Parker, 2011), among them poor health, socioeconomic 
disadvantage (Power et al., 2013), adverse childhood experiences (ACEs) (Felitti et al., 1998), low IQ 
(Calvin et al., 2011, 2017), and poor self-control (Moffitt et al., 2011).  
Markers of inflammation have played an important role in this research on the developmental origins of adult 
disease. In particular, given their predictive value for age-related disease and mortality, markers of 
inflammation have been used as intermediate endpoints for studies of early-life risk factors’ effects on adult 
health (Danese & Baldwin, 2017; Danese & McEwen, 2012). In addition, evidence that immune response is 
dysregulated in many psychiatric disorders—including depression, schizophrenia and autism—is prompting 
new hypotheses about the etiology of psychiatric disorders as well as motivating research into the possibility 
that psychiatric diseases might respond to anti-inflammatory medications (Friedrich, 2014). C-reactive 
protein (CRP) has been commonly used as the global measure of systemic inflammation both in clinical 
practice and in life-course research (Ridker, 2003); however, CRP is quite sensitive to short-term influences, 
e.g., small acute infections. Soluble urokinase plasminogen activator receptor (suPAR) is a newer biomarker 
of inflammation that likely captures different aspects of systemic inflammation than CRP (Desmedt et al., 
2017), although CRP and suPAR are positively correlated (Lyngbæk et al., 2013).  
suPAR is the soluble form of uPAR, a membrane-bound receptor that is expressed on immune and 
endothelial cells and involved in several cellular processes, including adhesion, differentiation, proliferation, 
and migration (Blasi & Carmeliet, 2002). Immune and pro-inflammatory conditions increase the expression 
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and cleavage of uPAR (Dekkers et al., 2000; Ostrowski et al., 2005). The resulting suPAR is a stable 
circulating molecule with intrinsic chemotactic properties (Resnati et al., 2002), and the level of suPAR is 
thought to reflect the overall immune activity of an individual (Desmedt et al., 2017). suPAR levels are 
elevated across a wide range of diseases (Rasmussen et al., 2016), including cardiovascular disease (Persson 
et al., 2014), type 2 diabetes (Guthoff et al., 2017), cancer (Sorio et al., 2011; Tarpgaard et al., 2015), renal 
disease (Hayek et al., 2015), and infections (Donadello et al., 2014). In addition, suPAR predicts mortality, 
both in the general population and in patient populations (Eugen-Olsen et al., 2010; Rasmussen et al., 2016). 
However, to date suPAR has not been incorporated into studies of early-life origins of poor late-life health, 
and it is relatively unknown in pediatric medical practice or research.  
We investigated the childhood developmental origins of elevated chronic inflammation by analyzing suPAR 
in adulthood in a population-representative birth cohort that gathered multiple prospective measures of 
childhood risk. We had three broad goals. First, we investigated how suPAR relates to other concurrent 
health measures in adulthood. Second, we studied how childhood risk factors are related to elevated suPAR 
in adulthood. Third, as CRP and suPAR may reflect different aspects of inflammation, we also compared the 
two biomarkers, and tested a combination of the two in relation to childhood risks. 
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METHODS 
Study design and population 
Participants are members of the Dunedin Multidisciplinary Health and Development Study, a longitudinal 
investigation of health and behavior in a representative birth cohort. Participants (N=1,037; 91% of eligible 
births; 52% male) were all individuals born between April 1972 and March 1973 in Dunedin, New Zealand 
(NZ), who were eligible based on residence in the province and who participated in the first assessment at 
age 3 years. The cohort represents the full range of socioeconomic status (SES) in the general population of 
NZ’s South Island and matches the NZ National Health and Nutrition Survey on key adult health indicators 
(e.g., body mass index (BMI), smoking, GP visits). Participants are primarily white; fewer than 7% self-
identify as having partial non-Caucasian ancestry, matching South Island demographics (Poulton, Moffitt, & 
Silva, 2015). Assessments were carried out at birth and ages 3, 5, 7, 9, 11, 13, 15, 18, 21, 26, 32, and the 
most recent data collection was completed in December 2012 at age 38 years, when 95% (N=961) of the 
1,007 participants still alive took part. At each assessment, each participant is brought to the research unit for 
a full day of interviews and examinations. Laboratory work was performed through June 2017. Blood from 
participants of Maori ancestry was not transported to Duke University for cultural reasons, and plasma 
samples were not available for participants who did not provide blood or due to phlebotomy or defrost cycle 
problems. The final study population comprised 837 participants. Living Study members who did not have 
suPAR data in adulthood did not differ from those who did have available suPAR data in terms of their 
childhood socioeconomic status (t=.65, p=.52), number of Adverse Childhood Experiences (t=1.58, p=.11), 
IQ (t=1.66, p=.10), or self-control (t=.94, p=.35), but they did have poorer childhood health (t=2.00, p=.05). 
The Otago Ethics Committee approved each phase of the study and informed consent was obtained from all 
participants.  
Measures 
Inflammatory biomarkers and white blood cell count 
Venepuncture at age-38 was performed between 4.15–4.45 pm for all participants. 
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Plasma suPAR (ng/mL) was analyzed with the suPARnostic AUTO Flex ELISA (ViroGates A/S, Birkerød, 
Denmark) according to the manufacturer’s instructions.  
Serum high-sensitivity C-reactive protein (hsCRP, mg/L) was measured on a Modular P analyzer (Roche 
Diagnostics GmbH, Mannheim, Germany) using a particle-enhanced immunoturbidimetric assay.  
In addition, we assayed two additional markers of inflammation.  Plasma interleukin-6 (IL-6, pg/mL) was 
measured on a Molecular Devices (Sunnyvale, CA) SpectraMax plus 384 plate reader using R&D Systems 
(Minneapolis, MN) Quantikine High sensitivity ELISA kit HS600B according to the manufacturer’s 
instructions. Plasma fibrinogen (g/L) was measured on a Sysmex CA-1500 or CS2100i using a fully 
automated cap piercing coagulation analyzer (Mahberg, Germany).  
White blood cells (WBCs), including total WBCs, neutrophils, lymphocytes, monocytes, eosinophils, and 
basophils, were measured by flow-cytometry using a semiconductor laser to produce forward and lateral 
scattered light. All WBC types were reported as x109/L.  
Clinical characteristics 
BMI (kg/m2), body temperature (°F), and use of anti-inflammatory medication (including statins, respiratory 
or systemic steroids, prophylactic aspirin, or non-steroidal anti-inflammatory, anti-gout, or anti-rheumatic 
drugs) were recorded at age-38.  
Week of menstrual cycle (days since last period began) was registered for female participants.  
Smoking was reported at age-38, grouping the participants into four groups: non-smoker, smoking <10 
cigarettes/day, 10-19 cigarettes/day, or ≥20 cigarettes/day. 
Childhood risk factors and adult health correlates  
Childhood risk factors, including poor health, socioeconomic disadvantage, ACEs, low IQ, and poor self-
control, are described in Table 1. These risk factors have been reported in previous publications. In addition, 
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we also report about health and functional correlates of inflammation at age-38, including self-reported 
health, an index of Biological Age, an index of facial aging, and telomere length (Table 1). 
[INSERT TABLE 1] 
Cumulative Childhood Risk index 
Cumulative Childhood Risk represents a count of the 5 risk factors, where 1 point was given for being in the 
quartile associated with highest risk for each of the five childhood risk factors investigated: poor childhood 
health, low childhood socioeconomic status, more adverse childhood experiences, low IQ, and low self-
control. 
Statistical analysis 
We calculated Pearson’s and Spearman’s correlation coefficients to test the associations between hsCRP or 
suPAR with clinical characteristics, other inflammatory biomarkers (IL-6, fibrinogen), and WBC counts.  
hsCRP was not normally distributed and was log-transformed for further analyses, as commonly done in the 
literature (The Emerging Risk Factors Collaboration, 2012). 
The association between childhood risk factors and hsCRP and suPAR and between hsCRP and suPAR and 
adult health outcomes was tested using Ordinary Least Squares regression, using continuous measures of 
hsCRP and suPAR. Multivariable regression analyses were adjusted for the covariates sex, BMI, and 
smoking, as these are the most common adjustments in research on inflammation . We report standardized 
regression coefficients (b) with standard errors (SEs). 
To analyze the effect of childhood risk factors on adult-combined CRP and suPAR, we created four groups 
of individuals characterized by: i) low CRP and low suPAR (N=546, 66%), ii) high CRP and low suPAR 
(N=119, 14%), iii) low CRP and high suPAR (N=118, 14%), and iv) high CRP and high suPAR (N=47, 6%). 
For CRP, we used the established clinical cut-off of 3 mg/L to identify persons with high CRP; thus, the 
label ‘high CRP’ indicates hsCRP>3 mg/L (N=166, 20%). A clinical cut-off for suPAR has not yet been 
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established, so to identify participants with high suPAR, we chose a cut-off corresponding to a similar 
percentage as for ‘high CRP’; thus, ‘high suPAR’ indicates suPAR>2.89 ng/mL (N=168, 20.1%). The 
association between childhood risk factors and the inflammation groups was tested using multinomial 
logistic regression. We report odds ratios (ORs) with 95% confidence intervals (CIs).  
 
A p<.05 was a priori designated statistically significant. Statistical analyses were performed in SAS 
Enterprise Guide 7.11 (SAS Institute Inc, Cary, NC).  
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RESULTS 
Correlations of hsCRP and suPAR with clinical characteristics, inflammatory biomarkers, and white 
blood cells 
Distributions of hsCRP and suPAR in the Dunedin cohort are shown in Figure S1. 
High hsCRP and high suPAR were both significantly correlated with female sex, high BMI, and smoking. Of 
note, hsCRP was more strongly correlated with BMI than was suPAR, while suPAR was more strongly 
correlated with smoking than was hsCRP (Table 2).  
High hsCRP and high suPAR were significantly but weakly correlated with each other (r=0.15) and both 
were correlated with elevated fibrinogen, IL-6, and WBC counts (Table 2).  
[INSERT TABLE 2] 
Associations of hsCRP and suPAR with health outcomes at age 38 years 
At age-38, high hsCRP and high suPAR were both associated with poor self-reported health and older 
Biological Age (Table 3). High suPAR was also significantly associated with older facial age. After 
controlling for sex and risk factors for poor adult health (i.e., BMI and smoking), high hsCRP remained 
significantly associated with older Biological Age, while high suPAR remained significantly associated with 
older Biological Age and older facial age (Table 3). When further controlling for hsCRP, suPAR still 
remained significantly associated with older Biological Age (b 0.09; SE 0.04; p=.009) and older facial age (b 
0.16; SE 0.04; p<.001). Neither hsCRP nor suPAR were significantly associated with telomere length. 
[INSERT TABLE 3] 
Childhood risk factors predict hsCRP and suPAR levels in adulthood 
Children in poorer health, from socioeconomically disadvantaged backgrounds, or with lower IQ had 
elevated hsCRP levels later in life, at age-38 (Table 4). Similarly, children in poorer health, from 
disadvantaged backgrounds, with more Adverse Childhood Experiences (ACEs), lower IQ, or poorer self-
control had elevated age-38 suPAR levels (Table 4). (Details about the correlations between the components 
11 
 
of ACEs and hsCRP or suPAR are presented in Table S1). After controlling for sex, BMI, and smoking, 
children who experienced more ACEs, had lower IQ, or poorer self-control still showed evidence of elevated 
age-38 suPAR, while none of the associations between childhood risk factors and age-38 hsCRP survived 
adjustment for the covariates sex, BMI, and smoking (Table 4).  
[INSERT TABLE 4] 
We aggregated the five childhood risk factors into a single Cumulative Childhood Risk index. Mean hsCRP 
and suPAR levels were plotted against the Cumulative Childhood Risk index (Figure 1A and 1B, 
respectively). Cumulative Childhood Risk was significantly related to both inflammatory biomarkers, 
although only the association with suPAR survived controls for sex, BMI, and smoking (Table 4).  
We further investigated whether the associations between childhood risk factors and elevated suPAR levels 
were independent of elevated hsCRP. After controlling for hsCRP, children who grew up in 
socioeconomically disadvantaged backgrounds (b -0.09; SE 0.03; p=.006), who experienced more ACEs (b 
0.20; SE 0.03; p<.001), had lower IQs (b -0.17; SE 0.03; p<.001), or poorer self-control (b 0.11; SE 0.03; 
p=.002) had elevated age-38 suPAR levels. Poor childhood health was not associated with elevated suPAR 
when controlling for hsCRP (b 0.05; SE 0.03; p=.18). Finally, Cumulative Childhood Risk was a significant, 
independent predictor of elevated suPAR, even when controlling for hsCRP (b 0.18; SE 0.03; p<.001). 
[INSERT FIGURE 1] 
Predicting combined hsCRP and suPAR in adulthood 
Using information about both hsCRP and suPAR to characterize inflammation in adulthood, we studied four 
groups of individuals: those with low levels of hsCRP and suPAR, elevated hsCRP only, elevated suPAR 
only, and elevated levels of both inflammatory biomarkers (Figure 1C). Children with high Cumulative 
Childhood Risk indices were significantly more likely to have elevated levels of both hsCRP and suPAR in 
adulthood (OR,1.38; 95% CI, 1.10–1.73). In addition, Cumulative Childhood Risk predicted elevated suPAR 
even in the absence of elevated hsCRP (OR, 1.20; 95% CI, 1.02–1.41); in contrast, Cumulative Childhood 
Risk was less strongly linked to elevated hsCRP in the absence of elevated suPAR (OR, 1.15; 95% CI, 0.97–
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1.35). (Table S4 presents the results for the Cumulative Childhood Risk index as well as for each of its 5 
constituent risk factors; see also Figure S2.)  
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DISCUSSION 
In this four-decade longitudinal study of a birth cohort, we tested the potential utility of using a new 
biomarker, suPAR, to understand the role of inflammation in the context of the developmental origins of 
health and disease. Three findings stand out about the measurement, prediction, and potential uses of this 
inflammatory biomarker. 
First, consistent with prior reports that suPAR predicts disease and mortality (Eugen-Olsen et al., 2010), we 
observed that elevated suPAR, like hsCRP, is associated with poor health at midlife, as reflected in cohort 
members’ self-awareness of their own physical well-being, accelerated biological aging, and even their facial 
appearance. This suggests that suPAR captures health-relevant information about the burden of systemic 
inflammation in the body, even in early midlife and in a relatively healthy birth cohort. 
Second, children exposed to known risk factors for disease and early mortality, including poor health, 
socioeconomic disadvantage, more ACEs, low IQ, or poor self-control, had elevated suPAR levels as adults. 
The association between childhood risk factors and suPAR remained after controlling for key risk factors for 
poor adult health, including BMI and smoking. Prospective assessment of childhood risk factors ensured that 
there was no ascertainment bias or recall bias. Our finding that these childhood risk factors contribute to 
elevated adulthood inflammation is consistent with previous findings (Baumeister, Akhtar, Ciufolini, 
Pariante, & Mondelli, 2015; Slopen et al., 2015), including in this cohort (Danese, Pariante, Caspi, Taylor, & 
Poulton, 2007), using other inflammatory biomarkers, most notably hsCRP but also IL-6, fibrinogen, and 
tumor necrosis factor-α. Of interest, the associations between childhood risks and adult suPAR levels were 
less affected by adjustments for covariates than were associations between childhood risks and hsCRP, 
possibly because suPAR is less sensitive to acute circumstances and may better reflect chronic inflammation.  
Third, suPAR levels appear to add information about health implications of childhood risks above and 
beyond hsCRP, as childhood risk factors, excepting childhood health, remained significantly associated with 
adult suPAR when controlling for hsCRP levels. In addition, we observed the strongest associations between 
childhood risk and adulthood inflammation when combining information about both high hsCRP and high 
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suPAR, suggesting that hsCRP and suPAR, and maybe other inflammatory biomarkers, should be used 
together when estimating inflammatory burden that may be linked to childhood risks.  
These findings suggest that suPAR may be a useful tool in conceptualizing and measuring the early-life 
origins of inflammatory processes in disease and aging (Danese & Baldwin, 2017). As a biochemical 
analyte, suPAR is a very stable protein that can be easily measured in fresh or frozen plasma or serum 
samples and does not vary greatly in terms of pre- and post-sampling procedures (food intake, time of day, 
etc.) (Andersen, Eugen-Olsen, Kofoed, Iversen, & Haugaard, 2008). Clinical studies have found suPAR to be 
associated with incidence and prevalence of disease and with disease severity and prognosis. This applies to 
acute as well as chronic diseases and infectious as well as non-communicable diseases, including clinical 
conditions investigated in children (Schaefer et al., 2017; Şirinoğlu et al., 2017; Wittenhagen et al., 2011; 
Wrotek, Jackowska, & Pawlik, 2015). suPAR appears to reflect the health status or inflammatory burden of 
an individual, and chronic multimorbid patients have higher suPAR levels than patients with fewer chronic 
diseases (Rasmussen et al., 2016), while healthy people have low suPAR levels (Haupt et al., 2014). In the 
general population, suPAR has been found to increase with age and unhealthy lifestyle, with smoking and 
morbid obesity being major drivers of increased suPAR levels (Haupt et al., 2014). Of note, one study 
showed favorable lifestyle changes are reflected in reduced suPAR levels (Eugen-Olsen, Ladelund, & 
Sørensen, 2016), suggesting that suPAR may provide an outcome measure for studies of potential 
“reversibility” of chronic inflammation resulting from early-life risk exposures.  
Previous research has suggested that hsCRP and suPAR reflect different aspects of inflammation (Lyngbæk 
et al., 2013); while hsCRP is an acute-phase reactant associated with acute and metabolic inflammation, 
suPAR seems to be a marker of chronic rather than acute inflammation. In line with this, we found that 
hsCRP and suPAR were only weakly positively correlated with each other, and although both were 
correlated with other measures of inflammation, including WBCs, fibrinogen, and IL-6, suPAR showed a 
weaker correlation with fibrinogen and IL-6. In addition, hsCRP was positively correlated with clinical 
factors that could influence acute inflammation, such as body temperature, menstruation, and use of anti-
inflammatory medication, while suPAR was not associated with these. 
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The present study has limitations. First, we studied a single New Zealand birth cohort that lacked ethnic 
minority representation. Replications are needed in diverse populations. Second, suPAR was only measured 
once, at age-38. Since blood for the assay was not biobanked during childhood, we were unable to 
investigate changes in suPAR levels from childhood to midlife. Longitudinal studies of suPAR are needed. 
Third, although the distributional properties of suPAR are appealing for research purposes, the optimal 
threshold for its use as diagnostic biomarker has not yet been estimated. Fourth, the detected effect sizes 
were modest for both suPAR and hsCRP, although this is to be expected in a general population of generally 
healthy persons at midlife. Moreover, once we turned to examine cumulative risk, the effect sizes increased 
considerably, underscoring the conceptual and practical importance of evaluating multiple risk factor 
exposures rather than any single exposure (Evans, Li, & Whipple, 2013). Fifth, we were able to identify risk 
factors associated with elevated suPAR levels, but due to the observational study design, we cannot rule out 
non-causal alternative explanations of these associations. It would be informative to incorporate suPAR into 
randomized clinical trials of interventions intended to reduce effects of childhood risk factors (Moffitt, 
2013). Finally, it should be noted that the relation between suPAR and hsCRP may be different in clinical 
populations with specific diseases than in a relatively healthy population like the present.   
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CONCLUSION 
The findings suggest several implications.  First, the results strengthen the theory that adult inflammation has 
origins in childhood (Danese & Baldwin, 2017). Second, future life-course research about inflammation 
could add suPAR as an adjunct to hsCRP, as a new measure that may reflect additional long-term 
inflammatory processes. It is noteworthy that childhood risk factors were prominent in the group of 
participants with low hsCRP and high suPAR—a group that would inadvertently have been assigned to the 
low inflammation group if suPAR had not been measured. Moreover, the combination of hsCRP and suPAR 
may strengthen etiological research about the origins of adult inflammation. Third, the results provide further 
impetus to add measurements of inflammatory phenotypes into research programs aimed at understanding 
the origins of adult disease and improving lifelong health.   
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-  
  
KEY POINTS  
- Childhood risks—including poor health, socioeconomic disadvantage, Adverse Childhood 
Experiences (ACEs), low IQ, and poor self-control—have been associated with adult 
inflammation. It is unknown whether exposure to these early-life risks is associated with the 
novel chronic inflammation marker, suPAR.  
- In the longitudinal Dunedin Study, we found that children, who experienced childhood poor 
health, socioeconomic disadvantage, ACEs, low IQ, or poor self-control, had elevated suPAR as 
adults.  
- High midlife suPAR was associated with older biological age and older facial age. 
- Elevated suPAR added information beyond the oft-used inflammatory marker CRP.  
- Results strengthen the theory that adult inflammation has its origins in childhood. 
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FIGURE LEGENDS 
Figure 1. 
Relationship between hsCRP, suPAR, and Cumulative Childhood Risk in the Dunedin study. 
Mean (95%CI) age-38 (A) log-transformed hsCRP and (B) suPAR plotted against Cumulative Childhood 
Risk Index. (C) Mean (95%CI) Cumulative Childhood Risk Index scores of individuals stratified by high 
CRP (hsCRP>3 mg/L) and high suPAR (>2.89 ng/mL) levels. Dotted line: mean of reference group. 
 
  
27 
 
TABLES 
Table 1. Description of study measures 
Measure Description 
Childhood measures 
Childhood 
health 
Childhood health was measured from a panel of biomarkers and clinical ratings taken at 
assessments from birth to age 11 years (Belsky, Caspi, Israel, et al., 2015), including motor 
development (at ages 3, 5, 7, and 9 years), overall health (at ages 3, 5, 7, 9, and 11 years; rated 
by two Unit staff members based on review of birth records and assessment dossiers including 
clinical assessments and reports of infections, diseases, injuries, hospitalizations, and other 
health problems collected from children’s mothers during standardized interviews), body mass 
index (at ages 5, 7, 9, and 11 years), tricep and subscapular skinfold thicknesses (at ages 7 and 9 
years), and, finally, forced expiratory volume in one second (FEV1) and the ratio of FEV1 to 
forced vital capacity (FEV1/FVC; at ages 9 and 11 years). To calculate the childhood health 
measure, assessments were standardized to have mean = 0 and SD = 1 within age- and sex-
specific groups. Cross-age scores for each measure were then computed by averaging 
standardized scores across measurement ages. The final childhood health score was calculated 
by taking the natural log of the average score across all measures, resulting in a normally 
distributed childhood health index. High scores indicate poor health. 
 
Childhood 
socioeconomic 
status  
The socioeconomic statuses of cohort members’ families were measured using a 6-point scale 
that assessed parents’ occupational statuses, defined based on average income and educational 
levels derived from the New Zealand Census. The highest occupational status of either parent 
was averaged across the childhood assessments (Poulton et al., 2002). 
 
Adverse 
childhood 
experiences 
(ACEs) 
 
The measured ACEs correspond to the 10 subcategories of childhood adversity introduced by 
the U.S. Centers for Disease Control & Prevention (CDC) Adverse Childhood Experiences 
Study (“Center for Disease Control and Prevention,” n.d.; Felitti et al., 1998); i.e. three types of 
abuse (emotional, physical, sexual), five types of household challenges (household partner 
violence, household substance abuse, mental illness in household, loss of a parent (parental 
death, separation, or divorce), incarceration of a family member), and two types of neglect 
(emotional, physical). Prospective ACE counts were generated from archival Dunedin Study 
records collected at biennial assessments from ages 3 to 15 years, as previously described 
(Reuben et al., 2016). The records included the following: social service contacts; structured 
notes from assessment staff who interviewed Study children and their parents; structured notes 
from pediatricians and psychometricians who observed mother-child interactions at the research 
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unit; structured notes from nurses who recorded conditions witnessed at home visits; and notes 
of concern from teachers who were surveyed about the Study children’s behavior and 
performance. Separately, parental criminality was surveyed via postal questionnaire to the 
parents.  
 
Childhood IQ Middle-childhood intelligence was measured as previously described (Moffitt et al., 2011) using 
the Wechsler Intelligence Scale for Children-Revised (Wechsler, 1974). The participants’ total 
scores were averaged over the three assessment points to represent intelligence in middle-to-late 
childhood.  
 
Childhood low 
self-control 
 
Children’s self-control during their first decade of life was measured using a multi-
occasion/multi-informant strategy and was reported as a composite measure of overall self-
control, as previously described (Moffitt et al., 2011). The composite measure of self-control 
includes observational ratings of children’s lack of control; parent and teacher reports of 
impulsive aggression; parent, teacher, and self-reports of hyperactivity; lack of persistence; 
inattention; and impulsivity. Furthermore, at ages 3 and 5 years, the children’s lack of control in 
cognitive and motor tasks was rated by examiners blinded to the children’s behavioral history. 
At ages 5, 7, 9, and 11 years, parents and teachers completed the Rutter Child Scale (RCS), 
which included items indexing impulsive aggression and hyperactivity. At ages 9 and 11 years, 
the RCS was supplemented with additional questions about the children’s lack of persistence, 
inattention, and impulsivity. At age 11 years, the children were interviewed by a psychiatrist and 
reported about their symptoms of hyperactivity, inattention, and impulsivity. The 9 measures of 
self-control were standardized and averaged into a single composite score (M=0, SD=1).  
Adulthood measures 
Self-reported 
health 
Self-reported health was measured at age 38 years using a 5-point scale to rate the question: ‘In 
general, would you say your health is?’ The five options were ‘excellent’, ‘very good’, ‘good’, 
‘fair’, or ‘poor’.  
 
Biological Age The cross-sectional index of Biological Age (Levine, 2013) is an algorithm for estimating “rate 
of senescence” based on 10 biomarkers developed with parameters from the NHANESIII dataset 
using the Klemera-Doubal method (Klemera & Doubal, 2006). The ten biomarkers in the 
algorithm are: albumin, alkaline phosphatase, blood pressure (systolic), C-reactive protein, 
creatinine, cytomegalovirus IgG, forced expiratory volume in one second (FEV1), glycated 
hemoglobin (HbA1c), total cholesterol, and urea nitrogen. As previously described in the 
Dunedin Study, Biological Age at the age-38 assessment ranged from 28.65 to 61.97 years 
(M=38.29, SD=3.22) (Belsky, Caspi, Houts, et al., 2015). 
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Facial aging Facial aging was based on two measurements of perceived age based on facial photographs as 
previously described (Belsky, Caspi, Houts, et al., 2015). First, Age Range was assessed by an 
independent panel of 4 raters, who were presented with standardized (non-smiling) facial 
photographs of participants and were kept blind to their actual age. Raters used a Likert scale to 
categorize each study member into a 5-year age range (i.e. from 20 to 24 years old up to 65 to 70 
years old). Scores for each study member were averaged across all raters (α=0.71). Second, 
Relative Age was assessed by a different panel of raters, who were told that all photos were of 
people aged 38 years old. Raters then used a 7-item Likert scale to assign a “relative age” to 
each study member (1=”young looking”, 7=”old looking”). Scores for each study member were 
averaged across all raters (α=0.72). The measure of perceived age at 38 years, facial age, was 
derived by standardizing and averaging Age Range and Relative Age scores.  
 
Telomere length Leukocyte DNA was extracted from blood using standard procedures (Bowtell, 1987; 
Jeanpierre, 1987). DNA was stored at -80°C until assayed to prevent degradation of the samples. 
All DNA samples were assayed for leukocyte telomere length at the same time, using a 
validated quantitative PCR method (Cawthon, 2002), as previously described (Shalev et al., 
2014), which determines mean telomere length across all chromosomes for all cells sampled. 
The method involves two quantitative PCRs for each subject, one for a single-copy gene and the 
other in the telomeric repeat region. All DNA samples were run in triplicate for telomere and 
single-copy reactions, i.e., six reactions per study member. 
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Table 2. Sex-adjusted correlates of hsCRP and suPAR at age 38 years in the Dunedin study 
  Mean (SD) 
or  
N (%) 
hsCRPa  suPAR 
Variable  N rb p  N rb p  
Clinical characteristics         
  Sex (Female) 414 (49.5%) 830 -0.11 .002  837 -0.16 <.001 
  BMI (kg/m2) 27.1 (5.3) 828 0.45 <.001  828 0.07 .04 
  Smoking 173 (20.7%) 829 0.07 .04  836 0.36 <.001 
  Body temperature (°F) 97.6 (0.7) 830 0.09 .01  837 -0.02 .52 
  Week of menstrual cyclec 2.64 (1.08) 352 0.10 .05  352 0.04 .43 
  Anti-inflammatory medication 254 (30.4%) 829 0.10 .006  836 0.002 .94 
Inflammatory biomarkers         
  hsCRPa (mg/L) 2.39 (3.83)     830 0.15 <.001 
  suPAR (ng/mL) 2.40 (0.91) 830 0.15 <.001     
  Fibrinogen (g/L) 2.72 (0.57) 819 0.61 <.001  819 0.19 <.001 
  IL-6 (pg/mL) 1.55 (1.61) 790 0.44 <.001  790 0.08 .02 
White blood cell count         
  White blood cells (x109/L) 7.90 (1.80) 827 0.22 <.001  827 0.22 <.001 
  Neutrophils (x109/L) 4.52 (1.39) 827 0.22 <.001  827 0.16 <.001 
  Lymphocytes (x109/L) 2.47 (0.66) 827 0.09 .01  827 0.18 <.001 
  Monocytes (x109/L) 0.66 (0.19) 827 0.18 <.001  827 0.18 <.001 
  Eosinophils (x109/L) 0.22 (0.15) 827 0.01 .76  827 0.05 .17 
  Basophils (x109/L) 0.02 (0.04) 827 -0.10 .006  827 0.04 .29 
BMI, body mass index; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; SD, standard deviation; suPAR, 
soluble urokinase plasminogen activator receptor. aLog-transformed hsCRP (natural logarithm); bPearson’s and 
Spearmans’s correlation coefficients for continuous and categorical variables, respectively; cDays since last menstrual 
period began. 
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Table 3. Associations of hsCRP and suPAR with health outcomes at age 38 years in the Dunedin study 
  hsCRPa  suPAR 
  Unadjusted  Adjustedb  Unadjusted  Adjustedb 
Health outcomes N b (SE) p  b (SE) p  b (SE) p  b (SE) p 
Self-reported health 827 -0.16 (0.03) <.001  -0.04 (0.04) .28  -0.16 (0.03) <.001  -0.07 (0.04) .06 
Biological Agec 827 0.33 (0.03) <.001  0.19 (0.04) <.001  0.18 (0.03) <.001  0.11 (0.04) .004 
Facial aging 827 0.05 (0.03) .13  0.01 (0.04) .88  0.23 (0.03) <.001  0.16 (0.04) <.001 
Telomere length 811 -0.02 (0.03) .66  -0.01 (0.04) .73  -0.04 (0.04) .24  -0.04 (0.04) .29 
hsCRP, high-sensitivity C-reactive protein; SE, standard error; suPAR, soluble urokinase plasminogen activator receptor. aLog-transformed hsCRP (natural 
logarithm); bAdjusted for sex, body mass index, and smoking; cThe cross-sectional index of Biological Age at age-38 was calculated using the Klemera-Doubal 
equation for the following 10 biomarkers (see Table 1): albumin, alkaline phosphatase, blood pressure (systolic), CRP, creatinine, cytomegalovirus IgG, forced 
expiratory volume in one second (FEV1), glycated hemoglobin (HbA1c), total cholesterol, and urea nitrogen. Thus, hsCRP is part of this measure.  
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Table 4. Associations of childhood risk factors with hsCRP and suPAR at age 38 years in the Dunedin study 
  hsCRPa  suPARb 
  Unadjusted  Adjustedc  Unadjusted  Adjustedc 
Childhood risk factors N b (SE) p  b (SE) p  b (SE) p  b (SE) p 
Poor health  786 0.11 (0.04) .002  -0.03 (0.03) .44  0.08 (0.03) .03  0.05 (0.03) .16 
Socio-economic status  823 -0.11 (0.03) .002  -0.02 (0.03) .57  -0.12 (0.03) <.001  -0.04 (0.03) .23 
ACEs  827 0.04 (0.03) .25  -0.03 (0.03) .42  0.20 (0.03) <.001  0.10 (0.03) .003 
IQ  807 -0.11 (0.03) .002  -0.01 (0.03) .71  -0.18 (0.03) <.001  -0.08 (0.03) .01 
Poor self-control  827 0.06 (0.03) .08  0.03 (0.03) .37  0.12 (0.03) <.001  0.07 (0.03) .05 
Cumulative Childhood Riskd,e 826 0.09 (0.03) .007  -0.01 (0.03) .67  0.20 (0.03) <.001  0.10 (0.03) .002 
ACE, adverse childhood experiences (prospective); hsCRP, high-sensitivity C-reactive protein; IQ, intelligence quotient; SE, standard error; suPAR, soluble 
urokinase plasminogen activator receptor. aLog-transformed hsCRP (natural logarithm); bResults for untransformed and log-transformed suPAR are shown in 
Table S2; cAdjusted for sex, body mass index, and smoking; dCumulative Childhood Risk represents a count of the 5 risk factors, where 1 point was given for 
being in the quartile associated with highest risk for each of the five childhood risk factors investigated: poor childhood health, low childhood socioeconomic 
status, more adverse childhood experiences, low IQ, and low self-control; eHistorically, the epidemiological literature has also focused on measures associated 
with blood thickness and clotting, most often using the biomarker fibrinogen. We therefore repeated analyses reported here for Cumulative Childhood Risk, but 
also using fibrinogen in Table S3. 
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Figure 1 
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Table S1. Sex-adjusted spearman correlations of Adverse Childhood Experiences (ACEs), 
single components of ACEs, and an index of childhood maltreatment with hsCRP or suPAR at 
age 38 years. The table first shows the associations between ACEs and each of the two 
inflammatory markers, in shaded grey. Next, the table shows the associations between each of the 10 
components that make up the ACEs measure and each of the two inflammatory markers. Finally, the 
table shows the associations between an index of maltreatment (which is made up of indicators of 
abuse and neglect (as in ACEs), and caregiver changes) and each of the two inflammatory markers.   
    Spearman Correlations 
  hsCRP
a 
(N=830) 
suPAR  
(N=837) 
 N (%) r p R P  
 
    
ACEs  
476 (56.9%)  0.050 .15 0.167 <.001 
   None 361 (43.1%)     
   1 269 (32.1%)     
   2 103 (12.3%)     
   3     56 (6.7%)     
   4+     48 (5.7%)     
ACEs components 
     
   Family Incarceration 94 (11.2%) -0.022 .52 0.053 .13 
   Family Substance Problems 43 (5.1%)  0.031 .37 0.114 .001 
   Family Mental Illness 159 (19.0%) -0.005 .88 0.092 .008 
   Parental Separation, Divorce or   Death 231 (27.6%) 0.026 .45 0.118 <.001 
   Family Violence 86 (10.3%) -0.016 .65 0.042 .23 
   Physical Abuse 120 (14.3%)  0.049 .16 0.097 .005 
   Physical Neglect 21 (2.5%)  0.024 .49 0.060 .08 
   Emotional Abuse 37 (4.4%)  0.010 .76 -0.010 .78 
   Emotional Neglect 68 (8.1%) 0.026 .46 0.102 .003 
   Sexual Abuse 2 (0.2%) 0.036 .29 0.040 .25 
Maltreatmentb 294 (35.1%) 0.079 .02 0.117 <.001 
   None 543 (64.9%)     
   Probable 225 (26.9%)     
   Severe 69 (8.2%)     
aLog-transformed hsCRP (natural logarithm); bAn index of maltreatment which is made up of indicators of abuse 
and neglect (as in ACEs) and caregiver changes. 
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Table S2. Results for untransformed and log-transformed suPAR  
  suPAR  LN(suPAR) 
  Unadjusted  Adjusteda  Unadjusted  Adjusteda 
Childhood risk factors N b (SE) P  b (SE) p  b (SE) p  b (SE) p 
Poor health  786 0.08 (0.03) .03  0.05 (0.03) .16  0.09 (0.04) .008  0.06 (0.03) .07 
SES 823 -0.12 (0.03) <.001  -0.04 (0.03) .23  -0.10 (0.03) .003  -0.03 (0.03) .43 
ACEs  827 0.20 (0.03) <.001  0.10 (0.03) .003  0.20 (0.03) <.001  0. 09 (0.03) .005 
IQ  807 -0.18 (0.03) <.001  -0.08 (0.03) .01  -0.19 (0.03) <.001  -0.08 (0.03) .01 
Poor self-control  827 0.12 (0.03) <.001  0.07 (0.03) .05  0.12 (0.03) <.001  0.07 (0.03) .03 
Cumulative Childhood Risk 826 0.20 (0.03) <.001  0.10 (0.03) .002  0.20 (0.03) <.001  0.10 (0.03) .003 
aAdjusted for sex, body mass index, and smoking; ACE, adverse childhood experiences (prospective); IQ, intelligence quotient; SE, standard error; 
suPAR, soluble urokinase plasminogen activator receptor. 
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Table S3. Associations of Cumulative Childhood Risk with fibrinogen at age 38 years in the Dunedin study 
 hsCRPa  Fibrinogen  suPAR 
 N b (SE) p  N b (SE) p  N b (SE) p 
Unadjusted  818 0.10 (0.04) .006  818 0.07 (0.04) .06  818 0.20 (0.03) <.001 
Adjusted for hsCRP  - - -  818 0.006 (0.03) .82  818 0.15 (0.03) <.001 
Adjusted for fibrinogen 818 0.06 (0.03) 0.04  - - -  818 0.20 (0.03) <.001 
Adjusted for suPAR 818 0.07 (0.04) 0.06  818 0.02 (0.04) .49  - - - 
Full modelb 818 0.05 (0.03) 0.07  818 -0.02 (0.03) 0.57  818 0.19 (0.03) <.001 
aLog-transformed hsCRP; bFull model with hsCRP, fibrinogen, and suPAR; hsCRP, high-sensitivity C-reactive protein; SE, standard 
error; suPAR, soluble urokinase plasminogen activator receptor. 
  
 37 
 
 
Table S4. Associations of childhood risk factors with elevated inflammation groups at age 38 years 
 Low CRP, low suPARa High CRP, low suPARa Low CRP, high suPARa High CRP, high suPARa 
 (N=546) (N=119) (N=118) (N=47) 
Childhood risk 
factors 
N (%) OR 
N 
(%) 
OR (95% CI) p 
N 
(%) 
OR (95% CI) p 
N 
(%) 
OR (95% CI) p 
Cumulative 
Childhood Riskb 
545 1.00 117 1.21 (1.02–1.44) .03 118 1.27 (1.08–1.50) .004 46 1.45 (1.14–1.83) .002 
Poor health 520 1.00 112 1.23 (0.99–1.54) .06 110 1.20 (0.97–1.50) .10 44 1.43 (1.03–1.99) .03 
Socioeconomic status  543 1.00 117 0.83 (0.69–0.99) .04 117 0.89 (0.74–1.06) .19 46 0.67 (0.50–0.89) .006 
ACEs 546 1.00 117 1.01 (0.85–1.21) .91 118 1.28 (1.09–1.50) .002 46 1.28 (1.01–1.62) .04 
IQ 531 1.00 117 0.99 (0.97–1.00) .07 114 0.98 (0.96–0.99) .003 45 0.96 (0.94–0.98) <.001 
Poor self-control  546 1.00 117 0.99 (0.80–1.23) .94 118 1.18 (0.97–1.44) .10 46 1.48 (1.14–1.93) .004 
aHigh CRP: high-sensitivity CRP > 3 mg/L. High suPAR: suPAR > 2.89 ng/ml; bThe Cumulative Childhood Risk index was assessed using a 5-point 
score, where 1 point was given for being in the quartile associated with highest risk for each of the five childhood risk factors investigated, ie, poor 
childhood health, low childhood socioeconomic status, more adverse childhood experiences, low IQ, and poor self-control; ACE, adverse childhood 
experience; CRP, C-reactive protein; IQ, intelligence quotient; suPAR, soluble urokinase plasminogen activator receptor. 
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Figure S1 
 
 
Distributions of high-sensitivity C-reactive protein (hsCRP) and soluble urokinase plasminogen activator 
receptor (suPAR) in the Dunedin cohort at age 38 years. Despite not looking entirely normally distributed, the 
deviation in suPAR distribution did not affect the models, and the results were the same when we log-
transformed the variable (Table S2). 
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Figure S2 
 
Mean values of childhood risk factors plotted against elevated inflammation groups at age 38 years based on high-sensitivity C-reactive protein 
(hsCRP) and soluble urokinase plasminogen activator receptor (suPAR) levels. “High CRP” indicates hsCRP values >3 mg/L, and “High suPAR” 
indicates suPAR values >2.89 ng/mL. Circles and error bars indicate means with 95% confidence intervals. Compared with the group of participants 
who had low inflammation (low hsCRP and low suPAR), average childhood health was significantly poorer in participants with high hsCRP and low 
suPAR (p=.04); childhood SES was significantly lower for participants with high hsCRP and low suPAR (p=.05) or with both high hsCRP and high 
suPAR (p=.007); mean number of ACEs was significantly higher for participants with low hsCRP and high suPAR (p=.002) as well as participants with 
 40 
 
high hsCRP and high suPAR (p=.03); childhood IQ was significantly lower for both groups with high suPAR (p=.002 and p<.001, respectively); and the 
degree of low self-control was significantly higher for participants with high hsCRP and high suPAR (p=.005)
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